Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

138.85 +1.05 (+0.76%)
Streaming Delayed Price Updated: 9:51 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces First Quarter 2025 Financial Results
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference
From iRhythm
Via GlobeNewswire
iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025
From iRhythm
Via GlobeNewswire
iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability
Report highlights progress against key sustainability initiatives that reflect iRhythm’s commitment to delivering better data, better insights, and better health for all 
From iRhythm
Via GlobeNewswire
iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection
Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor... 
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From iRhythm
Via GlobeNewswire
iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic... 
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
From iRhythm
Via GlobeNewswire
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients 
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
From iRhythm
Via GlobeNewswire
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
From iRhythm
Via GlobeNewswire
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
From iRhythm
Via GlobeNewswire
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM)... 
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Results of GUARD-AF Trial
From iRhythm
Via GlobeNewswire
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in Upcoming Investor Conferences in September
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Chief Financial Officer Transition
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Second Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.